Stocks 22nd Sep '22 Preclinical Upfronts Interesting dataset showing that, despite a fairly constant $ amount of upfront payments, its % of a total biotech licensing deal’s value has fallen to a low for pre-clinical assets. Click to share on Twitter (Opens in new window)Click to email a link to a friend (Opens in new window)Click to share on LinkedIn (Opens in new window)
